ClinicalTrials.gg
CompletedNCT03485911APeX-2Updated Jun 26, 2023Results posted

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

A Phase 3 interventional study of BCX7353 capsules and Placebo oral capsule in Hereditary Angioedema and HAE, sponsored by BioCryst Pharmaceuticals. Completed at 47 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by BioCryst Pharmaceuticals · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies testing berotralstat in Angioedemas, Hereditary — 1 open to participants now, 2 under way, 2 of them phase 3. berotralstat · Angioedemas, Hereditary.

Enrollment
4th of 11
121 · median 58
Started
2018
with 2 others
Phase 3
4 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
11 of 11
BioCryst Pharmaceuticals

Among the 11 studies testing berotralstat in Angioedemas, Hereditary, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 8th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies testing berotralstat in Angioedemas, Hereditary is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About berotralstat

berotralstat: first FDA approval 2020 (ORLADEYO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing berotralstat in Angioedemas, Hereditary, or all of them as a file.
02

Study summary

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

03

Conditions studied

  • Hereditary Angioedema
  • HAE

Keywords

  • BCX7353
  • Berotralstat
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A clinical diagnosis of hereditary angioedema Type 1 or Type 2, defined as having a C1-INH functional level and a C4 level below the lower limit of the normal (LLN) reference range, as assessed during the Screening period.
  • Subject weight of ≥ 40 kg
  • Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE
  • Subjects must be medically appropriate for on-demand treatment as the sole medicinal management for their HAE during the study.
  • Subjects must have a specified number of investigator-confirmed attacks during the run-in period of a maximum of 56 days from the Screening visit.
  • Acceptable effective
  • Written

Key Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Any medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
  • Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
  • Severe to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
  • Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study
  • Current participation in any other drug study or received another investigational drug within 30 days of the Screening visit
  • Prior enrollment in a BCX7353 study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    BCX7353 110 mg once daily

    BCX7353 administered as oral capsules once daily

    Drug: BCX7353 capsules

  • Experimental
    BCX7353 150 mg once daily

    BCX7353 administered as oral capsules once daily

    Drug: BCX7353 capsules

  • Placebo comparator
    Placebo

    Matching placebo administered as oral capsules once daily

    Drug: Placebo oral capsule

Interventions

  • BCX7353 oral capsules administered once daily

    Also known as: Berotralstat

  • DrugPlacebo oral capsule

    Matching oral capsules administered once daily

06

What researchers measure

Primary outcomes

  1. Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)

    Treatment comparisons between each berotralstat dose and placebo in the rate of investigator-confirmed HAE attacks during the Part 1 dosing period were analyzed using a negative binomial model. The number of investigator-confirmed attacks was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline attack rate) was included as a covariate, and the logarithm of duration on treatment was included as an offset variable. The estimated attack rate for each treatment group, the treatment differences expressed as the attack rate ratio (berotralstat over placebo rate ratio), and the associated 95% confidence intervals (CIs) were provided from the negative binomial model.

    Time frame: 24 weeks

  2. Part 2 & 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE

    The safety data was assessed for the safety population, for subjects who entered Part 2 and Part 3, and includes TEAEs that began in Part 2 or 3, respectively, for these subjects. Safety data for Part 2 and Part 3 is combined to clearly show TEAEs occurring in subjects as the proceeded through the 2 study parts. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 2 or Part 3 treatment). No statistical analysis was performed on this safety data.

    Time frame: Part 2: 24 weeks (Days 169 to 337). Part 3: 48 weeks (Days 338 to 674).

Secondary outcomes

  1. Part 1: Change From Baseline in Angioedema Quality of Life Questionnaire at Week 24 (Total Score)

    Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.

    Time frame: Baseline and 24 weeks

  2. Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks

    Assessment of proportion of days subjects had angioedema symptoms from expert-confirmed HAE attacks during Part 1.

    Time frame: 24 weeks

  3. Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period

    The rate of expert-confirmed HAE attacks for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.

    Time frame: Day 8 through to 24 weeks (or or the last dose date/time in Part 1 + 24 hours for subjects who discontinued drug in Part 1)

  4. Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 48 Week Period

    Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.

    Time frame: 24 weeks (Days 169 to 337)

  5. To Evaluate Angioedema Quality of Life Questionnaire (Total Score) Following Berotralstat Administration for up to 144 Weeks

    Angioedema-specific QoL was assessed by the AE-QoL, consisting of 4 domains (i.e., functioning, fatigue/mood, fears/shame, and nutrition) and a total score. The AE-QoL scores range from 0 points (best QoL) to 100 points (worst QoL). A decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL was completed by the subjects at each visit starting at baseline, and questions were answered with regard to the previous 28 days. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

    Time frame: Up to 144 weeks

  6. To Evaluate Treatment Satisfaction Questionnaire for Medication (TSQM) Following Berotralstat Administration for up to 144 Weeks

    The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

    Time frame: Up to 144 weeks

07

Results

Posted Mar 2, 2021

Participant flow

Part 1
Participant flow — Part 1
MilestoneTreatment Group 1 (110 mg Berotralstat QD)Treatment Group 2 (150 mg Berotralstat QD)Treatment Group 3aTreatment Group 3b
Started41402020
Completed37371717
Not completed4333
Withdrew: Perceived lack of efficacy1120
Withdrew: Subject withdrew consent0101
Withdrew: Lab abnormalities/aes3110
Withdrew: Withdrew consent prior to dosing0001
Withdrew: Other nos0001
Part 2
Participant flow — Part 2
MilestoneTreatment Group 1 (110 mg Berotralstat QD)Treatment Group 2 (150 mg Berotralstat QD)Treatment Group 3aTreatment Group 3b
Started37371717
Completed28311514
Not completed9623
Withdrew: Perceived lack of efficacy5302
Withdrew: Subject withdrew consent1021
Withdrew: Lab abnormalities/aes1200
Withdrew: Other nos0100
Withdrew: Intercurrent illness/new medical condition1000
Withdrew: Investigator judgement1000
Part 3
Participant flow — Part 3
MilestoneTreatment Group 1 (110 mg Berotralstat QD)Treatment Group 2 (150 mg Berotralstat QD)Treatment Group 3aTreatment Group 3b
Started26261514
Completed7454
Not completed19221010
Withdrew: Perceived lack of efficacy2220
Withdrew: Subject withdrew consent1401
Withdrew: Lab abnormalities/aes1102
Withdrew: Other nos1100
Withdrew: Intercurrent illness/new medical condition0110
Withdrew: Sponsor discontinuation1000
Withdrew: Berotralstat provided by alternative means131377

Outcome measures

PrimaryPart 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)

Treatment comparisons between each berotralstat dose and placebo in the rate of investigator-confirmed HAE attacks during the Part 1 dosing period were analyzed using a negative binomial model. The number of investigator-confirmed attacks was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline attack rate) was included as a covariate, and the logarithm of duration on treatment was included as an offset variable. The estimated attack rate for each treatment group, the treatment differences expressed as the attack rate ratio (berotralstat over placebo rate ratio), and the associated 95% confidence intervals (CIs) were provided from the negative binomial model.

Time frame:
24 weeks
Reported as:
Number · HAE attack rate per 28 days
Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)
HAE attack rate per 28 daysBerotralstat 110 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)1.651.312.35
Statistical analysis
  • Berotralstat 110 mg Once Daily vs Placebo · negative binomial regression model · p = 0.024 · Negative binomial regression model: 30.0 · 95% CI 4.6 to 48.7
  • Berotralstat 150 mg Once Daily vs Placebo · negative binomial regression model · p = <0.001 · Negative binomial regression model: 44.2 · 95% CI 23.0 to 59.5
PrimaryPart 2 & 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE

The safety data was assessed for the safety population, for subjects who entered Part 2 and Part 3, and includes TEAEs that began in Part 2 or 3, respectively, for these subjects. Safety data for Part 2 and Part 3 is combined to clearly show TEAEs occurring in subjects as the proceeded through the 2 study parts. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 2 or Part 3 treatment). No statistical analysis was performed on this safety data.

Time frame:
Part 2: 24 weeks (Days 169 to 337). Part 3: 48 weeks (Days 338 to 674).
Reported as:
Count of participants · Participants
Part 2 & 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE
ParticipantsPart 2: 110mg BerotralstatPart 2: 110mg Berotralstat After PlaceboPart 2: 150mg BerotralstatPart 2: 150mg Berotralstat Following PlaceboPart 3: Berotralstat
TEAE2213271267
Drug-related TEAE457712
TESAE00117
Drug-related TESAE00000
DMID grade 3 or 4 TEAE112110
Drug-related DMID grade 3 or 4 TEAE00101
TEAE leading to interruption of study drug01215
TEAE leading to discontinuation of study drug10223
Drug-related investigator-identified rash00100
GI abdominal-related TEAE5410918
GI abdominal-related TEAE -study drug discontinued10112
SecondaryPart 1: Change From Baseline in Angioedema Quality of Life Questionnaire at Week 24 (Total Score)

Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · AE-QoL Total Score Change from baseline
Part 1: Change From Baseline in Angioedema Quality of Life Questionnaire at Week 24 (Total Score)
AE-QoL Total Score Change from baselineBerotralstat 110 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Part 1: Change From Baseline in Angioedema Quality of Life Questionnaire at Week 24 (Total Score)-12.46 ± 2.530-14.59 ± 2.592-9.69 ± 2.643
Statistical analysis
  • Berotralstat 110 mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.453 · Mean difference (final values): -2.77 · 95% CI -10.08 to 4.53
  • Berotralstat 150 mg Once Daily vs Placebo · mixed-model repeated measures analysis · p = 0.188 · Mean difference (final values): -4.90 · 95% CI -12.23 to 2.43
SecondaryPart 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks

Assessment of proportion of days subjects had angioedema symptoms from expert-confirmed HAE attacks during Part 1.

Time frame:
24 weeks
Reported as:
Least squares mean · Proportion days with angioedema symptoms
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks
Proportion days with angioedema symptomsBerotralstat 110 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks0.134 ± 0.01910.119 ± 0.01940.197 ± 0.0196
Statistical analysis
  • Berotralstat 110 mg Once Daily vs Placebo · ANCOVA · p = 0.025 · Difference in least square means: -0.062 · 95% CI -0.117 to -0.008
  • Berotralstat 150 mg Once Daily vs Placebo · ANCOVA · p = 0.006 · Difference in least square means: -0.078 · 95% CI -0.133 to -0.023
SecondaryPart 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period

The rate of expert-confirmed HAE attacks for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.

Time frame:
Day 8 through to 24 weeks (or or the last dose date/time in Part 1 + 24 hours for subjects who discontinued drug in Part 1)
Reported as:
Mean · HAE attack rate per 28 days
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period
HAE attack rate per 28 daysBerotralstat 110 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period1.918 ± 1.73451.552 ± 1.63902.490 ± 1.6135
Statistical analysis
  • Berotralstat 110 mg Once Daily vs Placebo · negative binomial regression model · p = 0.026 · Negative binomial regression model: 30.4 · 95% CI 4.3 to 49.3
  • Berotralstat 150 mg Once Daily vs Placebo · negative binomial regression model · p = <0.001 · Negative binomial regression model: 46.5 · 95% CI 25.6 to 61.5
SecondaryPart 2: To Assess the Effectiveness of Berotralstat Over a 24- to 48 Week Period

Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.

Time frame:
24 weeks (Days 169 to 337)
Reported as:
Mean · HAE attack rate-change from baseline
Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 48 Week Period
HAE attack rate-change from baselinePart 2: 110mg BerotralstatPart 2: 150mg Berotralstat
Month 6-1.383 ± 1.7289-1.593 ± 1.6581
Month 7-1.229 ± 1.8158-1.903 ± 1.7402
Month 12-1.543 ± 1.6539-1.910 ± 1.5330
SecondaryTo Evaluate Angioedema Quality of Life Questionnaire (Total Score) Following Berotralstat Administration for up to 144 Weeks

Angioedema-specific QoL was assessed by the AE-QoL, consisting of 4 domains (i.e., functioning, fatigue/mood, fears/shame, and nutrition) and a total score. The AE-QoL scores range from 0 points (best QoL) to 100 points (worst QoL). A decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL was completed by the subjects at each visit starting at baseline, and questions were answered with regard to the previous 28 days. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

Time frame:
Up to 144 weeks
Reported as:
Mean · AE-QoL score - change from baseline
To Evaluate Angioedema Quality of Life Questionnaire (Total Score) Following Berotralstat Administration for up to 144 Weeks
AE-QoL score - change from baselineBerotralstat 110/150 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Week 4-5.85 ± 15.478-9.70 ± 15.346-7.762 ± 15.098
Week 8-10.58 ± 15.968-13.09 ± 19.064-11.33 ± 16.732
Week 12-11.51 ± 14.354-13.95 ± 17.652-10.63 ± 18.376
Week 18-9.97 ± 16.809-15.13 ± 14.946-12.48 ± 19.752
Week 24-9.80 ± 16.145-12.81 ± 19.181-12.51 ± 20.371
Week 48-10.19 ± 14.128-13.78 ± 16.219—
Week 72-12.34 ± 16.909-13.02 ± 16.276—
Week 96-12.81 ± 16.593-17.92 ± 17.161—
Week 120-15.24 ± 18.026-17.24 ± 14.943—
Week 144-11.29 ± 17.165-11.65 ± 16.558—
SecondaryTo Evaluate Treatment Satisfaction Questionnaire for Medication (TSQM) Following Berotralstat Administration for up to 144 Weeks

The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.

Time frame:
Up to 144 weeks
Reported as:
Mean · TSQM Global score - change from baseline
To Evaluate Treatment Satisfaction Questionnaire for Medication (TSQM) Following Berotralstat Administration for up to 144 Weeks
TSQM Global score - change from baselineBerotralstat 110/150 mg Once DailyBerotralstat 150 mg Once DailyPlacebo
Week 4-1.3 ± 31.752.4 ± 31.91-18.1 ± 35.44
Week 84.3 ± 31.512.1 ± 31.66-19.2 ± 40.41
Week 124.4 ± 33.034.3 ± 31.32-21.1 ± 44.15
Week 18-1.8 ± 33.02-3.8 ± 32.69-18.9 ± 39.59
Week 243.1 ± 33.692.9 ± 33.96-20.8 ± 42.52
Week 485.4 ± 31.526.7 ± 28.87—
Week 7211.0 ± 30.4310.9 ± 22.88—
Week 9613.9 ± 30.1614.5 ± 22.31—
Week 12012.7 ± 29.5514.6 ± 20.75—
Week 1444.5 ± 39.118.7 ± 22.79—

Adverse events

Collected over Adverse Events (AEs) were assessed and recorded from the time that the Informed consent form was signed through the last follow-up visit, approximately 3 weeks following the last dose of study drug, or until the AE was resolved or the subject was in a clinically stable condition with regards to the AE.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Berotralstat 110mg Once Daily0/57 (0%)5/57 (8.8%)56/58 (96.6%)
Berotralstat 150mg Once Daily0/58 (0%)5/58 (8.6%)53/57 (93%)
Placebo0/39 (0%)2/39 (5.1%)30/39 (76.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
Diverticulum intestinal haemorrhagicGastrointestinal disorders0/570/581/39
PneumoniaInfections and infestations1/570/581/39
Transient ischaemic attackNervous system disorders0/570/581/39
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/570/580/39
Pleural effusionRespiratory, thoracic and mediastinal disorders1/570/580/39
Bipolar disorderPsychiatric disorders1/570/580/39
Gastritis alcoholicGastrointestinal disorders1/570/580/39
ObesityMetabolism and nutrition disorders1/570/580/39
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/571/580/39
Medical observationInvestigations0/571/580/39
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBerotralstat 110mg Once DailyBerotralstat 150mg Once DailyPlacebo
NasopharyngitisInfections and infestations15/5819/579/39
NauseaGastrointestinal disorders10/5811/577/39
Abdominal painGastrointestinal disorders4/5810/572/39
VomitingGastrointestinal disorders5/589/571/39
Upper respiratory tract infectionInfections and infestations8/589/571/39
DiarrhoeaGastrointestinal disorders7/588/570/39
Abdominal discomfortGastrointestinal disorders3/588/573/39
DyspepsiaGastrointestinal disorders8/587/573/39
Gastroesophageal reflux diseaseGastrointestinal disorders7/584/570/39
Urinary tract infectionInfections and infestations7/582/570/39

Baseline characteristics

Intent to treat population

Age, Continuous
Age, Continuous(years)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
Mean40.4 ± 17.5140.0 ± 13.9844.5 ± 14.1241.6 ± 15.32
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
Female30232780
Male11171341
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
Hispanic or Latino0213
Not Hispanic or Latino393838115
Unknown or Not Reported2013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American2125
White383837113
More than one race0112
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
Canada43310
Austria1214
Romania0101
Hungary2002
United States28242577
Czechia2338
North Macedonia0112
United Kingdom1427
France2013
Germany1225
Spain0022
Baseline Investigator-confirmed attack rate
Baseline Investigator-confirmed attack rate(Participants)Part 1: Berotralstat 110 mg Once DailyPart 1: Berotralstat 150 mg Once DailyPart 1: PlaceboTotal
≥ 2 HAE attacks/month28302785
< 2 HAE attacks/month13101235
08

Study locations

47 sites
  • Study center
    Birmingham, Alabama 35209, United States
  • Study center
    Scottsdale, Arizona 85251, United States
  • Study center
    Little Rock, Arkansas 72205, United States
  • Study Center
    San Diego, California 92122, United States
  • Study center
    Santa Monica, California 90404, United States
  • Study Center
    Walnut Creek, California 94598, United States
  • Study center
    Colorado Springs, Colorado 80907, United States
  • Study Center
    Tampa, Florida 33613, United States
  • Study center
    Chevy Chase, Maryland 20815, United States
  • Study Center
    Boston, Massachusetts 02114, United States
  • Study Center
    Ann Arbor, Michigan 48106, United States
  • Study center
    Plymouth, Minnesota 55446, United States
  • Study Center
    Saint Louis, Missouri 63141, United States
  • Study center
    Belleville, New Jersey 07109, United States
  • Study Center
    Fair Lawn, New Jersey 07410, United States
  • Study center
    Piscataway, New Jersey 08854, United States
  • Study Center
    New York, New York 10029, United States
  • Study Site
    Charlotte, North Carolina 28277, United States
  • Study Center
    Durham, North Carolina 27705, United States
  • Study Center
    Cincinnati, Ohio 45231, United States
  • Study center
    Columbus, Ohio 43235, United States
  • Study center
    Clackamas, Oregon 97015, United States
  • Study Center
    Hershey, Pennsylvania 17033, United States
  • Study center
    Austin, Texas 78731, United States
  • Study center
    Dallas, Texas 75231, United States
  • Study Center
    San Antonio, Texas 78229, United States
  • Study Center
    Spokane, Washington 99202, United States
  • Study Center
    Vienna, 1090, Austria
  • Study Center
    Ottawa, Ontario K1G 6C6, Canada
  • Study Center
    Toronto, Ontario M4V 1R2, Canada
  • Study Center
    Québec, G1V 4W2, Canada
  • Study Center
    Brno, 656 91, Czechia
  • Study Center
    Plzen, 30460, Czechia
  • Study Center
    Grenoble, 38043, France
  • Study Center
    Paris, 75012, France
  • Study Center
    Berlin, 10117, Germany
  • Study Center
    Frankfurt, D-60590, Germany
  • Study Center
    Budapest, H-1225, Hungary
  • Study Center
    Skopje, 1000, North Macedonia
  • Study Center
    Sângeorgiu de Mureș, Jud. Mureș 547530, Romania
  • Study Center
    Barcelona, 08907, Spain
  • Study Center
    Madrid, 28046, Spain
  • Study Center
    Seville, 41013, Spain
  • Study Center
    Cambridge, CB2 0QQ, United Kingdom
  • Study Center
    Frimley, GU16 7UJ, United Kingdom
  • Study Center
    London, E1 2ES, United Kingdom
  • Study Center
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗
  • Wedner HJ, Aygoren-Pursun E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). J Allergy Clin Immunol Pract. 2021 Jun;9(6):2305-2314.e4. doi: 10.1016/j.jaip.2021.03.057. Epub 2021 Apr 15. PubMed 33866032 ↗
  • Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlikova J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Epub 2020 Oct 21. PubMed 33098856 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2019, 14 months.

Results were first posted in Mar 2021, 1 year 10 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 14 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2018
First posted
Apr 3, 2018
StartActual
Feb 6, 2018
Primary completionActual
Apr 10, 2019
CompletionActual
Apr 6, 2022
Results first posted
Mar 2, 2021
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03485911
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Feb 6, 2018
Primary completion
Apr 10, 2019
Completion
Apr 6, 2022
Results posted
Mar 2, 2021
Last update
Jun 26, 2023

Study contacts

Bruce Zuraw, MD
principal investigator · UC San Diego School of Medicine, US HAE Angioedema Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berotralstat

Start the discussion